<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381899</url>
  </required_header>
  <id_info>
    <org_study_id>BR-1</org_study_id>
    <nct_id>NCT02381899</nct_id>
  </id_info>
  <brief_title>Observational Study in CLL Patients Receiving BR</brief_title>
  <official_title>Observational Study in Comorbid Patients With Chronic Lymphocytic Leukemia Receiving First-line Bendamustine With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Czech CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Czech CLL Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to provide additional data to confirm the safety
      profile and efficacy of bendamustine and rituximab (BR) chemotherapy for chronic lymphocytic
      leukemia patients with significant comorbidities treated in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BR (bendamustine, rituximab) combination is currently accepted as a first-line treatment of
      chronic lymphocytic leukemia (CLL) in patients for whom fludarabine combination chemotherapy
      is not appropriate.

      The objective of this observational study is to provide additional data to confirm the safety
      profile and efficacy of BR for CLL patients treated in routine clinical practice.

      Specific data of interest are: comorbid conditions, CLL characteristics, adverse events,
      reasons for discontinuation BR, overall response rates, complete response rate,
      progression-free survival, overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) criteria</measure>
    <time_frame>8 months</time_frame>
    <description>Toxicity assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) criteria (myelotoxicity, infections, etc.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>8 months</time_frame>
    <description>Response to treatment was assessed using National Cancer Institute-sponsored Working Group criteria, including bone marrow examination and radiographic confirmation of complete response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Calculated from the start of therapy until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time interval from the start of therapy until death form any cause</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>BR in CLL</arm_group_label>
    <description>Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine and Rituximab</intervention_name>
    <description>Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>BR in CLL</arm_group_label>
    <other_name>Mabthera</other_name>
    <other_name>Levact</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphocytic leukemia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of chronic lymphocytic leukemia

          -  Patients treated with first-line BR for active disease requiring treatment

          -  Cumulative Illness Rating Scale (CIRS) &gt; 6

          -  Informed consent to data collection

        Exclusion Criteria:

          -  Patients treated with BR within prospective clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Spacek, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Czech CLL Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology - Oncology, University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>60500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4th Department of Medicine - Hematology, University Hospital</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, University Hospital</name>
      <address>
        <city>Plzen</city>
        <zip>30599</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine - Hematology, University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Department of Medicine - Hematology, General University Hospital</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.cll.cz</url>
    <description>Czech CLL Study Group</description>
  </link>
  <reference>
    <citation>Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012 Sep 10;30(26):3209-16. doi: 10.1200/JCO.2011.39.2688. Epub 2012 Aug 6.</citation>
    <PMID>22869884</PMID>
  </reference>
  <results_reference>
    <citation>Obrtlikova P, Spacek M, Doubek M, Hadrabova M, Panovska A, Svackova K, Trneny M. Bendamustine with rituximab (BR) is safe treatment option with high response rate for chronic lymphocytic leukemia in elderly patients with comorbidities. LEUKEMIA &amp; LYMPHOMA 56(1SI): 151-153, 2015 [abstract #180].</citation>
  </results_reference>
  <results_reference>
    <citation>Spacek M, Obrtlikova P, Hadrabova M, Cmunt E, Karban J, Molinsky J, Simkovic M, Mocikova H, Mohammadova L, Panovska A, Novak J, Smolej L, Doubek M, Trneny M. Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine. XVII International Workshop on CLL, New York, May 12-15, 2017 [abstract #148]</citation>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>bendamustine</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

